Gilead shows high cure rates for hepatitis C combo drug
This article was originally published in Scrip
Gilead Sciences said its once-daily combination drug showed high cure rates in hepatitis C patients in late-stage studies, results that will help the company make a case for approval early next year.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.